After only 6 weeks of treatment, gamma glutamyl transpeptidase (GGT) levels were reduced by 23% in the 400mg BID group (p<0.01) In patients with higher baseline GGT, reduction in GGT levels was even greater wi ...
Following successful CRADA collaboration data in preclinical ALS models, GeNeuro exercises option with the National Institute of Neurological Disorders and Stroke (NINDS) to secure worldwide development rights GeN ...
. Positive effects observed on key neuroprotection endpoints related to MS disease progression . Neuroprotective effects also seen in non-active MS patient . Confirmation of safety and tolerability Geneva, Switz ...
. GKT831 achieves marked anti-fibrotic effects in clinically relevant model of advanced cholestatic disease . Interim results of the Phase 2 Clinical Trial with GKT831 in Primary Biliary Cholangitis expected in early ...
. Data Demonstrate Potential of GKT831 to Efficiently Target Cancer Associated Fibroblasts . Interim results of the Phase 2 Trial with GKT831 in Primary Biliary Cholangitis expected in early November 2018 Genkyote ...
Geneva, Switzerland, 26 September 2018 – 7:30am CEST – GeNeuro (Euronext Paris: CH0308403085 - GNRO), a biopharmaceutical company developing new treatments for neurological and autoimmune diseases, announced that its Pha ...
